Takeaway

• SARS-CoV-2 mRNA-1273, BNT162b2, and Ad26.COV2.S vaccine effectiveness (VE) are associated with waning temporal protection against infection and symptomatic COVID-19, but VE against severe disease is preserved in most circumstances.

Why this matters

• Target booster doses first to patients of age ≥65 years,...